Treatment of high-risk patients with subvesical obstruction from advanced prostatic carcinoma using a thermosensitive mesh stent

British Journal of Urology

Volumn 80, Issue 4, 1997, Pages 623-627

  Gottfried, H W ^a   Gnann, R ^a   Brandle E ^a   Bachor, R ^a   Gschwend, J E ^a   Kleinschmidt, K ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Advanced prostatic carcinoma; High risk patients; Memotherm stent; Subvesical obstruction

Indexed keywords

ANDROGEN; BIOMATERIAL; METAL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLADDER NECK STENOSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; HEAT SENSITIVITY; HIGH RISK PATIENT; HORMONAL THERAPY; HUMAN; MALE; MICTURITION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE SURGERY; STENT; SYMPTOM; TRANSURETHRAL RESECTION; TREATMENT OUTCOME;

EID: 0031400392     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1997.00416.x     Document Type: Article

References (22)

1. Parker SL, Tang T, Bohler S, Wingo PA. Cancer statistics CA. Canc J Clin 1996; 46: 5-27
2. Enstein JI, Pizou G, Walsh DC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993; 71: 3582-93
3. Labrie F, Belanger A, Simand J, Labrie C, Dupont A. Combination therapy for prostate cancer. Cancer 1993; 71: 1059-67
4. Chute R, Willetts AT, Gens JP. Experiences in the treatment of carcinoma of the prostate with stilbestrol and with castration by the technique of intra-capsular orchiectomy. J Urol 1942; 48: 682-92
5. Fleischmann JD, Catalona NJ. Endocrine therapy for bladder outlet obstruction from carcinoma of the prostate. J Urol 1985; 134: 498-500
6. Huggins C, Hodges CV. Studies of prostatic cancer: I. Effect of castration, estrogen and androgen injections on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-7
7. Montie JE. The management of bladder outlet dysfunction due to prostate cancer, untreated and after endocrine treatment. Prostate 1992; 54 suppl 4: 153
8. Mommsen S, Petersen L. Transurethral catheter removal after bilateral orchiectomy for prostate carcinoma associated with acute urinary retention. Scand J Urol Nephrol 1993; 28: 401-4
9. Moul JW, Davis R, Vaccaro JA, Silhelnik SA, Belville WD, McLeod DG. Acute urinary retention associated with prostatic carcinoma. J Urol 1989; 141: 1375-7
10. Doll HA, Black NA, McPherson K, Flood AB, Williams GB, Smith JC. Mortality, morbidity and complications following transurethral resection of the prostate for benign prostatic hypertrophy. J Urol 1992; 147: 1566-73
11. Holtgrewe HL, Mebust WK, Dowd JB, Cockett AT, Peters PC, Proctor C. Transurethral prostatectomy: practice aspects of the dominant operation in American urology. J Urol 1989; 141: 248-53
12. Mebust WK, Holtgrewe HL, Cockett ATK, Peters PC. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3885 patients. J Urol 1989; 141: 243-7
13. Arcangeli G, Micheli A, Verna L et al. Prognostic impact of transurethral resection on patients irradiated for localized prostate cancer. Radiother Oncol 1995; 35: 123-8
14. Sandier HM, Hanks GE. Analysis of the possibility that transurethral resection promotes metastases in prostate cancer. Cancer 1988; 62: 2622
15. Chapple CR, Milroy EJ, Rickards D. Permanently implanted urethral stent for prostatic obstruction in the unfit patient - preliminary report. Urology 1990; 66: 58
16. Gottfried HW, Schimers HP, Gschwend J, Brändie E, Hautmann R. Initial experiences with the Memotherm® stent in treatment of benign prostatic hyperplasia. Urologe A 1995; 34: 110-8
17. Kaplan SA, Merrill DC, Mosely WG et al. The titanium intraprostatic stent: the United States experience. J Urol 1993; 150: 1624-9
18. Kirby RS, Heard SR, Miller P et al. Use of the ASI titanium stent in the management of bladder outflow obstruction due to benign prostatic hyperplasia. J Urol 1992; 148: 1195-7
19. Milroy E, Chapple CR. The urolume stent in the management of benign prostatic hyperplasia. J Urol 1993; 150: 1630-5
20. Oesterling JE, Kaplan SA, Epstein HB, Detalco AJ, Reddy PK, Chancellor MB. The North American experience with the Urolume endoprothesis as a treatment for benign prostatic hyperplasia: long term results. The North American Urolume Study Group. Urology 1994; 44: 363-4
21. Williams G, Coulange C, Milroy EJG, Sarramon JP, Rubben H. The Urolume, a permanently implanted prostatic stent for patients at high risk for surgery. Results from 5 collaborative centres. Br J Urol 1993; 72: 335-40
22. Guazzoni G, Montorsi F, Bergamaschi F, Consonni P, Rigatti P. Prostatic Urolume wallstent for urinary retention due to advanced prostate cancer: A 1 year follow-up. J Urol 1994; 152: 1530-2